Trial Profile
A Study Assessing Efficacy Of Paclitaxel In Combination With Bevacizumab (Avastin) For The Treatment Of Malignant Pleural Effusions (MPEs) In Patients With Non–Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Mar 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Malignant pleural effusion; Non-small cell lung cancer
- Focus Therapeutic Use
- 03 Mar 2017 New trial record